WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • WJPPS: MARCH ISSUE PUBLISHED
  • March Issue has been successfully launched on 1 March 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

Abstract

CLINICAL PHARMACOLOGY OF ERYTHROMYCIN IN INFANTS AND CHILDREN

*Gian Maria Pacifici

ABSTRACT

Erythromycin is a macrolide antibiotic binds reversibly to the 50S ribosomal subunits of susceptible organisms. Gram-positive microorganisms accumulate about 100 times more erythromycin than do gram-negative bacteria. Erythromycin is active against streptococci, Corynebacterium diphtheria, Listeria monocytogenes, Haemophilus influenzae, Neisseria gonorrhoea, Borrelia species, Bordetella pertussis, Clostridium jejuni, Moraxella pneumoniae, Legionella pneumophila, and most strains of Chlamydia trachomatis. Chlamydia trachomatis causes urethritis, epididymitis, pelvic inflammatory disease, hepatitis, and endometritis and these diseases are cured by erythromycin. Oral erythromycin base is incompletely absorbed but ester derivatives: stearate, estolate and ethylsuccinate have improved absorption-rates. Erythromycin is actively transported into the cell, where reaches antibacterial activity rapidly, accumulates in the liver, is excreted in the bile, and is metabolized by the superfamily CYP3A into N-demethylation erythromycin and erythromycin sulfoxide. Bacteroides fragilis, Streptococcus epidermis, Streptococcus pneumoniae, Neisseria meningitis, and Haemophilus influenzae cause meningitis and these organisms are inhibited by erythromycin. Prophylaxis with erythromycin has been found useful to prevent infective diseases. Erythromycin interacts with drugs and the interaction may be synergistic or antagonistic. This drug crosses the placenta and the concentration in the newborn infant blood is 3 to 4% of that in the maternal blood at delivery. Erythromycin causes toxicity and adverse-effects in infants and children. Some organisms may become resistant to erythromycin and macrolide consumption induces bacterial-resistance to erythromycin. The aim of this study is to review the published data on erythromycin dosing, pharmacokinetics, efficacy, safety, adverse-effects, drug-interactions, metabolism, meningitis, prophylaxis, placental-transfer, breast-milk migration, bacterial-resistance, infants, and children.

Keywords: erythromycin, dosing, drug-interactions, pharmacokinetics, treatment, bacterial-resistance.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More